PCRX vs COLL

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 10, 2026

PCRX

43.9
AI Score
VS
PCRX Wins

COLL

27.5
AI Score

Investment Advisor Scores

PCRX

44score
Recommendation
HOLD

COLL

28score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric PCRX COLL Winner
Forward P/E 9.8814 3.5778 COLL
PEG Ratio 0.9886 0.7157 COLL
Revenue Growth -1.6% 3.3% COLL
Earnings Growth 483.3% -29.0% PCRX
Tradestie Score 43.9/100 27.5/100 PCRX
Profit Margin 5.1% 4.7% PCRX
Beta 1.00 1.00 Tie
AI Recommendation HOLD AVOID NEW MONEY PCRX

Relative Price Performance (Last 90 Days)

PCRX 1M: +0.4% · 3M: +57.3% COLL 1M: +15.2% · 3M: -11.9%

Current Technical Phase

PCRX

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (17.9% over 20 days), RSI 82

RSI (14): 81.6 · Price: $36.46

COLL

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 60

RSI (14): 59.6 · Price: $24.81

Fundamentals Snapshot

Metric PCRX COLL
Market Cap — —
Forward P/E 10.5 3.5
Trailing P/E 39.2 22.4
Revenue (TTM) — —
Revenue Growth 0.0% 0.0%
Gross Margin 0.8% 0.9%
Operating Margin 0.1% 0.2%
EPS 0.93 1.09
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, PCRX is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.